Results 71 to 80 of about 2,842 (113)

Comparative outcomes of ceftazidime-avibactam versus meropenem-vaborbactam for KPC-producing Enterobacterales infections. [PDF]

Antimicrob Agents Chemother
Karaba SM, Hareza DA, Munita JM, Martinez JRW, Bergman Y, Hawes AM, Bulman ZP, Cosgrove SE, Simner PJ, Tamma PD.   +9 more
europepmc   +1 more source

Rapid meropenem/vaborbactam NP test for detecting susceptibility/resistance in Enterobacterales. [PDF]

J Antimicrob Chemother, 2023
Nordmann P, Kerbol A, Bouvier M, Sadek M, Poirel L, Raro OHF.   +5 more
europepmc   +1 more source

Successful Treatment with Imipenem/Cilastatin/ Relebactam of a Polymicrobial Bacteremia due to Meropenem/Vaborbactam-Resistant KPC-Kp and Enterococcus Faecalis. [PDF]

Mediterr J Hematol Infect Dis
Marzi F, Alessandri M, De Crescenzo V, Del Vecchio S, Radi S, Manini M.   +5 more
europepmc   +1 more source

Complete genome sequences of KPC-producing <i>Klebsiella pneumoniae</i> isolates pre- and post-development of meropenem/vaborbactam resistance. [PDF]

Microbiol Resour Announc
Ozer EA, Nozick SH, Singh N, Watkins JV, Hauser AR, Bulman ZP.   +5 more
europepmc   +1 more source

Aminoglycosides enhance meropenem/vaborbactam activity against KPC-producing <i>Klebsiella pneumoniae</i> in the hollow fiber infection model. [PDF]

Antimicrob Agents Chemother
Singh N, Jogan CML, Zang Y, Shan X, Lang Y, Karunanidhi A, Watkins JV, Curry BN, Tamma PD, Nozick SH, Ozer EA, Hauser AR, Bulitta JB, Bulman ZP.   +13 more
europepmc   +1 more source

Meropenem/Vaborbactam: β-Lactam/β-Lactamase Inhibitor Combination, the Future in Eradicating Multidrug Resistance. [PDF]

Antibiotics (Basel), 2023
Duda-Madej A, Viscardi S, Topola E.
europepmc   +1 more source

Targeting carbapenem-resistant and hypervirulent Klebsiella pneumoniae: in vitro evaluation of cefepime/zidebactam, aztreonam/avibactam, imipenem/relebactam, and meropenem/vaborbactam. [PDF]

BMC Infect Dis
Li Y, Li Y, Jia X, Mao H, Li D, Zhang J.
europepmc   +1 more source

Unlocking potentials: the impact of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam in combating carbapenem-resistant <i>Enterobacter cloacae</i>. [PDF]

Antimicrob Agents Chemother
Lavoie T, Sierra T, Daffinee K, Pogue JM, Achour B, LaPlante K.   +5 more
europepmc   +1 more source

Emergence of KPC-producing <i>Pseudomonas aeruginosa</i> in Spain: insights into an outbreak and resistance to the novel carbapenem/β-lactamase inhibitor combinations imipenem/relebactam and meropenem/vaborbactam. [PDF]

Antimicrob Agents Chemother
Pérez-Rodríguez G, Aja-Macaya P, González-Pinto L, Taltavull B, Tarriño-León M, Gallardo-García MdM, Blanco-Martín T, Rodríguez-Pallares S, Sánchez-Peña L, Moscoso M, Beceiro A, Oliver A, Bou G, Arca-Suárez J.   +13 more
europepmc   +1 more source

Meropenem/Vaborbactam in Pediatrics: 2 Cases of CRE Intraabdominal Infection. [PDF]

J Pediatr Pharmacol Ther
Sano U, Meyers R, Hasan U, Smoke S.
europepmc   +1 more source